Telesis Bio Inc. announced continued expansion of the BioXp Select product line, releasing two novel kits to enable DNA amplification and scale-up. The BioXp Select DNA Cloning and Amplification Kit and the BioXp Select Plasmid Amplification Kit enable on-demand and automated synthesis and amplification of transfection-scale DNA beginning from the customers own DNA fragments or plasmid DNA, overnight and at the push of a button. This is expected to enable researchers to optimize their discovery workflows by reducing the time and steps for cloning and scale-up of DNA required for their testing and analysis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.63 USD | -4.22% |
|
-17.50% | -49.46% |
May. 09 | Earnings Flash (TBIO) TELESIS BIO Reports Q1 Revenue $3.4M | MT |
May. 09 | Telesis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.46% | 6.38M | |
+4.98% | 217B | |
+7.44% | 191B | |
+28.22% | 154B | |
+33.19% | 112B | |
+1.22% | 62.75B | |
+16.51% | 53.34B | |
+1.45% | 48.88B | |
-4.53% | 39.36B | |
+2.74% | 35.73B |
- Stock Market
- Equities
- TBIO Stock
- News Telesis Bio, Inc.
- Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up